Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.85 |
| ▸ | MMP3 | P08254 | 8/20 | 0.85 |
| ▸ | MMP1 | P03956 | 2/20 | 0.85 |
| ▸ | MMP9 | P14780 | 2/20 | 0.85 |
| ▸ | MMP14 | P50281 | 2/20 | 0.85 |
| ▸ | CTPS1 | P17812 | 4/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 6/20 | 0.36 |
| ▸ | GUCY1B1 | Q02153 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965286 | 0.92 | MMP3 (1.00) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6960751 | 0.91 | MMP2 (0.87) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6586527 | 0.91 | MMP2 (0.71) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6588355 | 0.91 | MMP2 (0.70) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6585076 | 0.83 | MMP3 (1.00) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6435723 | 0.83 | MMP2 (0.84) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6972569 | 0.83 | MMP2 (0.84) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6433680 | 0.82 | MMP2 (0.82) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6435131 | 0.82 | MMP2 (0.72) | MMP2MMP3MMP1MMP9MMP14 | |
| Dimethylamine SCHEMBL6974207 | 0.82 | MMP3 (0.97) | MMP2MMP3MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | claimed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | claimed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | claimed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | claimed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |